Drug-resistant Tuberculosis Treatment Market Players:
- Johnson & Johnson
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Sanofi SA
- Endo International Plc
- Lupin
- Hikma Pharmaceuticals
- Pfizer Inc.
- STI Pharma LLC
- ANI Pharmaceuticals
- Thermo Fisher Scientific Inc.
The major players in the drug-resistant tuberculosis treatment market are offering a detailed portfolio of tuberculosis related medicines. These companies introduced advanced technologies that enable detailed visualization of test procedures.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of drug-resistant tuberculosis treatment is assessed at USD 1.77 billion.
The global drug-resistant tuberculosis treatment market size surpassed USD 1.68 billion in 2025 and is projected to witness a CAGR of more than 6.1%, crossing USD 3.04 billion revenue by 2035.
North America drug-resistant tuberculosis treatment market is anticipated to capture 35% share by 2035, driven by dominance of respiratory infections and large presence of key players in TB treatment.
Key players in the market include Johnson & Johnson, Novartis AG, Sanofi SA, Endo International Plc, Lupin, Hikma Pharmaceuticals, Pfizer Inc., STI Pharma LLC, Ani Pharmaceuticals, Thermo Fisher Scientific Inc..
